Retour
Fourchette du Jour
8,58 €
8,95 €
Fourchette 52 Semaines
8,50 €
14,87 €
Volume
94 310
Moyenne 50J / 200J
10,90 €
/
11,14 €
Clôture Précédente
8,81 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (627 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -5,2 | 0,3 |
| P/B | 1,7 | 2,9 |
| ROE % | -44,7 | 3,7 |
| Net Margin % | — | 3,8 |
| Rev Growth 5Y % | — | 10,0 |
| D/E | 0,0 | 0,2 |
Objectif de Cours des Analystes
Hold
21,67 €
+148.5%
Low: 18,00 €
High: 24,00 €
BPA Prévisionnel
-2,18 €
CA Est.
0
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2030 |
-2,31 €
-2,31 € – -2,31 €
|
17 M | 1 |
| FY2029 |
-2,08 €
-2,08 € – -2,08 €
|
0 | 1 |
| FY2028 |
-2,13 €
-2,47 € – -1,63 €
|
0 | 5 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 10, 2026 |
Mehra Uneek
Chief Financial Officer
|
grant | 128 330 | — | — |
| Mar 10, 2026 |
Beltran Pedro
Chief Scientific Officer
|
grant | 256 670 | — | — |
| Mar 10, 2026 |
Ben Yong
Chief Med & Dev Officer
|
grant | 256 670 | — | — |
| Jan 1, 2026 |
Wallace Eli M.
Chief Executive Officer
|
grant | 1 114 400 | — | — |
| Dec 10, 2025 |
Wallace Eli M.
Chief Executive Officer
|
sell | 1 114 400 | — | — |
| Oct 10, 2025 |
BridgeBio Pharma LLC
|
other | 784 720 | — | — |
| Oct 2, 2025 |
Wallace Eli M.
Chief Executive Officer
|
grant | 1 614 400 | — | — |
| Aug 26, 2025 |
Mehra Uneek
Chief Financial Officer
|
grant | 633 570 | — | — |
| Aug 26, 2025 |
Ben Yong
Chief Med & Dev Officer
|
grant | 357 177 | — | — |
| Aug 26, 2025 |
Tipirneni Praveen P.
|
grant | 52 269 | — | — |
| Aug 26, 2025 |
Wallace Eli M.
Chief Executive Officer
|
grant | 499 731 | — | — |
| Aug 26, 2025 |
Bauer Jake
|
grant | 138 193 | — | — |
| Aug 26, 2025 |
Beltran Pedro
Chief Scientific Officer
|
grant | 357 177 | — | — |
| Aug 26, 2025 |
MCCORMICK FRANK
|
grant | 91 076 | — | — |
| Aug 11, 2025 |
Chen Bihua
Director, 10% Owner
|
other | 8 344 252 | — | — |
| Aug 11, 2025 |
Chen Bihua
Director, 10% Owner
|
sell | 460 814 | — | — |
| Aug 11, 2025 |
Chen Bihua
Director, 10% Owner
|
grant | 10 950 408 | 10,72 € | — |
| Aug 11, 2025 |
McKenna Mark C.
|
other | 60 000 | — | — |
| Aug 11, 2025 |
Schmid John P.
|
other | 60 000 | — | — |
| Aug 11, 2025 |
Holman Albert A III
|
other | 60 000 | — | — |
Points Clés
Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -114,50M
PEG of 0,00 suggests growth is underpriced
Croissance
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-44,70%
ROIC-26,43%
Net MarginN/A
Op. MarginN/A
Sécurité
Debt / Equity
0,01
Current Ratio12,14
Interest Coverage0,00
Valorisation
P/E Ratio
-5,21
P/B Ratio1,70
EV/EBITDAN/A
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0,0 | Net Income (TTM) | -134,04M |
| ROE | -44,70% | ROA | -29,90% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -114,50M |
| ROIC | -26,43% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,01 | Current Ratio | 12,14 |
| Interest Coverage | 0,00 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | -5,21 | P/B Ratio | 1,70 |
| P/S Ratio | N/A | PEG Ratio | 0,00 |
| EV/EBITDA | N/A | Dividend Yield | 0,00% |
| Market Cap | 697,89M | Enterprise Value | 326,97M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Net Income | -134,04M | -74,28M | -64,70M | -3 520,0 | -43 357,0 |
| EPS (Diluted) | -4,30 | 0,46 | 0,00 | 0,00 | 0,00 |
| Gross Profit | -610 000,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Operating Income | -145,82M | -80,86M | -64,77M | -3 520,0 | -43 357,0 |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 448,38M | 194,42M | 332 894,0 | 144 578,0 | 144 281,0 |
| Total Liabilities | 37,29M | 5,71M | 396 463,0 | 166 455,0 | 162 638,0 |
| Shareholders' Equity | 411,10M | 188,72M | -63 569,0 | -21 877,0 | -18 357,0 |
| Total Debt | 2,77M | 0,0 | 70 095,0 | 43 106,0 | 36 961,0 |
| Cash & Equivalents | 373,69M | 1,70M | 0,0 | 0,0 | 0,0 |
| Current Assets | 425,46M | 1,95M | 0,0 | 0,0 | 0,0 |
| Current Liabilities | 35,04M | 187 515,0 | 396 463,0 | 166 455,0 | 162 638,0 |